Mental Health Clinics in Richland Center, WI Accepting Medicare
8 Mental Health Clinics found. Showing 1 - 8
 Pine Counseling Inc. Counselor - Addiction (Substance Use Disorder) Medicare: Medicare Enrolled Practice Location: 204 S Orange St, Richland Center, WI 53581 Phone: 931-982-4832 Fax: 608-383-1480 |
Richland County Health And Human Services Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 221 W Seminary St, Richland Center, WI 53581 Phone: 608-647-8821 Fax: 608-647-6611 |
Richland County Health And Human Services Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 221 W Seminary St, Richland Center, WI 53581 Phone: 608-647-8821 Fax: 608-647-6611 |
Richland County Health And Human Services Counselor - Addiction (Substance Use Disorder) Medicare: Medicare Enrolled Practice Location: 221 W Seminary St, Richland Center, WI 53581 Phone: 608-647-8821 Fax: 608-647-6611 |
New Day Couseling, Llc Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 149 E Mill St, Richland Center, WI 53581 Phone: 608-856-5225 Fax: 608-856-5226 |
Arneson Counseling Llc Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 165 N Central Ave, Richland Center, WI 53581 Phone: 608-521-0553 Fax: 608-571-6585 |
Pamela Nigl Llc Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 165 N Central Ave, Ste 110, Richland Center, WI 53581 Phone: 608-649-8181 Fax: 608-649-8181 |
Family Resources Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 165 N Central Ave, Suite 302,, Richland Center, WI 53581 Phone: 608-647-5076 Fax: 608-647-8444 |
News Archive
OBI advances Phase IIb clinical trial of Oxycyte for treatment of TBI
Oxygen Biotherapeutics, Inc., ("OBI") (NASDAQ: OXBT), today announced enrollment of the first subject in the second cohort of its global Phase IIb clinical trial to investigate the safety and tolerability of Oxycyte® in patients with severe, non-penetrating traumatic brain injury ("STOP-TBI").
Phase 3 study of idelalisibin reports positive results in CLL patients
Following a recommendation by an independent Data Monitoring Committee (DMC), Gilead Sciences, Inc. (Nasdaq:GILD) today announced that its Phase 3 study (Study 116) evaluating idelalisib in previously-treated chronic lymphocytic leukemia (CLL) patients who are not fit for chemotherapy will be stopped early.
Behavior influenced by our genes
A new study in Journal of Personality shows that selfless and social behavior is not purely a product of environment, specifically religious environment.
Older adults' symptoms of depression can be linked to higher risk of death
As we age, we become more likely to experience symptoms of depression. Research shows that depression's symptoms can be linked to a higher risk for death. Yet often, older adults' symptoms of depression may be missed by healthcare professionals.
› Verified 3 days ago